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Summary
Purpose. Inflammatory breast cancer (IBC) is the most aggressive form of locally advanced breast cancer (LABC).
The IBC phenotype is characterized by an infiltrative growth pattern, increased (lymph)angiogenesis and the
propensity to invade dermal lymphatics. In pancreatic cancer, interactions between caveolin-1 and RhoC GTPase, a
key molecule in causing the IBC phenotype, regulate tumour cell motility and invasion. In this study we sought to
investigate the role of caveolin-1 and -2 in IBC cell lines and in human IBC samples.
Experimental design. Differential methylation techniques identified the methylation status of the caveolin-1
and -2 promoters in human mammary epithelial cells (HMECs) and the SUM149 cell line. In cell line experi-
ments, caveolin-1 and -2 mRNA and protein expression were compared in HMECs, MCF10A, the SUM102 non-
IBC cell lines and 2 IBC cell lines (SUM149 and SUM190). Furthermore, caveolin-1 and -2 mRNA and protein
expression were compared in human IBC and non-IBC samples using cDNA microarray, real-time qRT-PCR and
immunohistochemistry. Results were correlated with RhoC protein expression data.
Results. In the SUM149 cell line, the caveolin-1 and -2 promoter sites were hypomethylated. A significantly
increased expression of caveolin-1 and -2, both at the mRNA and protein level was found in IBC cell lines and in
human samples of IBC: caveolin-1 and -2 mRNA were respectively 1.7 (p = 0.02) and 2.2 (p = 0.03) fold more
expressed in IBC compared to non IBC and at the protein level, 41.4% of IBC specimens expressed either caveolin-1 or
-2, compared to 15.6% of non-IBC specimens (p = 0.03). Furthermore a correlation was found between RhoC
protein expression and caveolin-1 (p = 0.1) or caveolin-2 (p = 0.09) or either caveolin-1 or -2 protein expression
(p = 0.04).
Conclusions. Although considered a tumour suppressor in breast cancer, we demonstrated overexpression of
caveolin-1 and -2 in IBC cell lines and in human samples of IBC,most likely due to hypomethylation of their respective
promoters. These results confirm the distinctmolecular signature of IBC.Our data further suggest interaction between
RhoC GTPase and the caveolins in IBC.
Introduction
Inflammatory breast cancer (IBC) is a distinct and
aggressive subtype of locally advanced breast cancer
(LABC). At time of diagnosis virtually all patients have
lymph node involvement and 1/3 of the patients have
distant metastases, resulting in a very poor prognosis.
Even when receiving combined modality treatment
including neo-adjuvant chemotherapy, less than 50% of
IBC patients have an overall survival of more than
5 years [1]. The aggressive IBC phenotype is marked by a
diffusely infiltrative rather than nodule-forming growth
pattern, by increased angiogenesis and lymphangiogenesis
[2, 3] and by the propensity of IBC to invade the der-
mal lymphatics and metastasize early in the develop-
ment of the disease. It is the extraordinary invasiveness
of the disease that suggests an important role for fac-
tors involved in cell motility and migration in the
pathophysiology of IBC. Better understanding of the
molecular mechanisms involved in the IBC phenotype
can therefore lead to better understanding of the biology
of breast cancer and metastasis ‘an sich’.
Caveolin-1 is the major protein component of
caveolae: specialized lipid rafts that are recognized in
electron micrographs as 50–100 nm invaginations of the
plasma membrane [4]. Although similar in distribution
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and tissue expression to caveolin-1, caveolin-2 is less
extensively studied. Many receptors and signal trans-
duction molecules are concentrated within caveolae;
therefore caveolae are proposed to be able to integrate
and regulate cellular signalling pathways including
GTPases (i.e. Ras and RhoA). Caveolin-1 has been
shown to directly interact with small GTP binding
proteins such as RhoA, a homologue of RhoC (95%
identical) and with the epidermal growth factor receptor
(EGFR) [5–6]. Abnormal EGFR expression and acti-
vation, as is often found in IBC, can lead to caveolin-1
phosphorylation and subsequent cell motility [7–9].
Although other Rho-family members are detected in
human cancers, RhoC expression is associated with
particularly aggressive human cancers [10–25]. RhoC has
also been intimately linked to the unique IBC phenotype.
RhoC is overexpressed and active in the majority of IBC
and is involved in the motile, invasive, angiogenic and
metastatic phenotype through mitogen activated protein
kinase (MAPK) signaling. Overexpression of RhoC in
HMECs recapitulated the IBC phenotype with regards to
invasion, motility and angiogenesis [26–28]. Furthermore,
in tumours smaller than 1 cm, RhoC expression is a good
marker to identify breast cancer patients with increased
risk of developing metastases [29].
Therefore, the aim of this study was to investigate the
role of caveolin-1 and -2 in IBC. We studied the meth-
ylation status of the caveolin-1 and -2 promoters in IBC
cell lines. Subsequently, the expression of caveolin-1 and
-2 was compared, at the mRNA and protein level, in
IBC and non-IBC cell lines and in human samples of
IBC and non-IBC patients. Results were confronted
with cDNA microarray experiments comparing IBC and
non-IBC patient samples [30] and were correlated to




The SUM190, SUM149 and SUM102 cell lines were
maintained under defined culture conditions as previously
described [32–35]. E6/E7 immortalized human mammary
epithelial cells (HMECs: [36]) were grown in 5% FBS (Life
Technologies, Gaithersburg, MD)-supplemented Ham’s
F12 medium (Life Technologies) containing insulin,
hydrocortisone, epidermal growth factor and cholera
toxin (Sigma Chemical Co., St. Louis, MO). MCF10A
cells were maintained in serum free mammary epithelial
growthmedium (Clonetics, Rockland,ME) supplemented
with cholera toxin. All cell lines were kept at 37 C in a
90% air/10% CO2 atmosphere.
Differential methylation analysis
Genomic DNA (gDNA) was isolated from the
SUM149, HMECs and normal lymphocytes (isolated
from the patient whose tumour the SUM149 cell line
was isolated from) using Trizol (Invitrogen, Carlsbad,
CA). Two lg aliquots of gDNA were digested with
20 units of each RsaI, RsaI + MspI (a methylation
insensitive restriction enzyme), or RsaI + HpaI (a
methylation sensitive restriction enzyme) for 16 h at
37 C. Restriction enzymes were heat inactivated for
20 min at 65 C. The digested gDNAs were amplified by
arbitrarily primed PCR (AP-PCR) according to the
original published protocol [37] using a single-primer
(AACCCTCACCCTAACCCCGG) or two primers
(AACCCTCACCCTAACCGCGC+AACCCTCACAA
CCCGCG). PCR reactions were performed in a final
volume of 25 ll with the following components: 10 mM
Tris–HCl pH 8.3, 1.5 mM MgCl2, 50 mM KCl, 200 lM
dNTPs, 2 lCi c32P-dATP (MP Biomedicals, Irvine, CA) ,
25 pmol primer and 0.53 U Taq polymerase (Roche) at
94 C for 30 s, 40 C for 60 s and 72 C for 90 s for 5
cycles followed by 94 C for 15 s, 55 C for 15 s and
72 C for 60 s for 30 cycles. PCR products were sepa-
rated on an 8 M urea 6% polyacrylamide gel, dried to
filter paper and exposed to Kodak X-Omat film for 72 h
at RT. Differentially methylated products were excised,
eluted in TE buffer, reamplified by PCR, cloned into the
pGEM-T Easy vector system (Promega, Madison, WI)
and sequenced by the University of Michigan DNA
sequencing core. Sequences were submitted to BLASTN
(http://www.ncbi.nlm.nih.gov/BLAST/).
Semiquantitative RT-PCR
Total RNA was harvested from actively growing cells at
60% confluence using Trizol Reagent (Invitrogen) and
cDNAwasmade using theAMV-reverse transcriptase kit
(Promega). Caveolin-1 and -2 transcripts were PCR
amplified using 1:100 dilutions of caveolin specific prim-




GAPDH was amplified as a loading control. PCR prod-
ucts were separated on a 1.2% TAE agarose gel and
visualized by ethidiumbromide staining (SigmaChemical
Co.). The intensity of ethidium bromide stained PCR
products was measured using ImageJ (NIH shareware
program) on a negative image. Caveolin message levels
were calculated relative to GAPDH levels.
Western blot analysis
Cells were grown in 100 mm dishes until reaching 70%
confluence. Protein was harvested with 500 ll RIPA
buffer with the addition of 1 mM sodium orthovana-
date, 0.3 mg/ml aprotinin, and 0.1 mg/ml phenylmeth-
ylsulfonyl fluoride. Aliquots of 50 lg were mixed with
Laemmli buffer, heat denatured, separated by 12.5%
SDS-PAGE and transferred to nitrocellulose. Nonspe-
cific binding was blocked by 1 h incubation with 5%
powdered milk in Tris-buffered saline with 0.05% Tween
20 (Sigma Chemical Co.). Immobilized proteins were
probed using antibodies for caveolin-1 (clone 2297,
Transduction Laboratories, BD Biosciences, San Diego,
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CA) and caveolin-2 (clone 65, Transduction Laborato-
ries). Levels of actin were determined as loading controls
(actin antibody (C2), Santa Cruz Biotechnology, Santa
Cruz, CA). Protein bands were visualized by ECL and
exposed to hyperfilm (Amersham-Pharmacia Biotech,
Piscataway, NJ). Densitometry was performed using
ImageJ (NIH shareware program). Protein levels were
calculated relative to actin levels.
Statistical analysis
Statistics were performed using Prism4 (Graphpad Soft-
ware, San Diego, CA) graphing and statistics program.
Mean relative caveolin-1 and -2 mRNA and protein
expression were compared between cell lines, using One-
Way ANOVA statistics and Bonferroni’s post hoc testing.
Human tissue sample experiments
Tissue samples
All tumour specimens included in this study were ob-
tained pre-treatment (before any neo-adjuvant chemo-
and/or hormonal therapy) and after written informed
consent. All protocols were reviewed and approved by
the ethical committee of the General Hospital
Sint-Augustinus. For the cDNA microarray and quan-
titative RT-PCR experiments, tumour specimens of 17
consecutive IBC and 20 control non-stage matched pa-
tients with breast cancer were collected and snap-frozen
in liquid nitrogen. IBC cases were diagnosed by strictly
respecting the criteria mentioned by the American Joint
Committee on Cancer as T4d [38]. All IBC patients
presented with a recently developed diffuse enlargement
of the breast with redness and edema of more than one
third of the skin of the breast. The presence of tumour
emboli in dermal lymphatics was, as an isolated patho-
logical finding, not sufficient for the diagnosis of IBC.
The average age of the IBC patients was 59.9 years
(range: 40.5–80.1 years). The non-IBC control popula-
tion consisted of 6 T1, 4 T2, 7 T3 and 3 T4 breast tu-
mours. The average age of the non-IBC patients was
61.6 years (range: 42.1–77.8 years). All but one IBC and
all non-IBC resection specimens included for the qRT-
PCR and cDNA microarray analysis were also included
for the IHC analysis. Both groups were enlarged with 12
patients from whom no fresh frozen tissue was available.
Clinico-pathological characteristics are listed in Table 1.
Tumour size, lymph node status and estrogen receptor
and progesterone receptor status were recorded by re-
view of pathology files. Tumours were subtyped as
ductal, lobular or special type (medullary, mucinous,
tubular,. . .) carcinoma and histologically graded as I-III
according to the Nottingham modification of the Bloom
and Richardson histological grading scheme.
cDNA microarrays and Real-Time quantitative Reverse
Transcriptase-PCR
Total RNA was extracted with the RNeasy Mini RNA
isolation kit (Qiagen, Valencia, CA). The Agilent
Bioanalyzer (Agilent Technologies, Palo Alto, CA) was
used to assess the quality of the RNA. The cDNA
microarray experiments were performed as described
before [30]. Briefly, one microgram of total RNA of each
sample was reverse transcribed, amplified and labelled
with Cy5 using the Amino Allyl MessageAmp aRNA
Amplification Kit (Ambion, Woodward, TX). Reference
RNA (Universal Human Reference RNA, Stratagene, La
Jolla, CA) was processed accordingly and was labelled
with Cy3. Sample and reference were competitively
hybridized onto cDNA microarray slides obtained from
the Sanger Center (Hixton, Cambridge, UK) as part of
the Ludwig Institute for Cancer Research/Cancer Re-
search United Kingdom (LICR/CRUK) Microarray
Consortium. These slides were made by linking PCR
products of cDNA clones on 3D-linked activated glass
slides. Each array contained 10750 spots, representing
9932 sequence-validated cDNA elements of 6000 known
and named human genes/ESTs. Slides were incubated
16 h at 47 C, washed and scanned using ScanArray
(Perkin–Elmer Life and Analytical Sciences, Boston,
MA) software. Data were normalized, analysed as de-
scribed before [30].
For the RT-PCR experiments, one microgram of
total RNA was reverse transcribed into cDNA with
random primers with High-Capacity cDNA Archive kit














Small (<2 cm) 10 *










Positive (>10%) 21 11
Negative (<10%) 11 19
PR
Positive (>10%) 15 9
Negative (<10%) 17 21
* In IBC, exact tumour size cannot be assessed neither clinically, nor
pathologically due to the diffuse enlargement of the breast and the
diffusely infiltrative growth pattern of the tumour (ER, estrogen
receptor; PR, progesterone receptor).
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(Applied Biosystems, Foster City, CA). PCR primers
and TaqMan probes targeting caveolin-1 and -2, 18S
rRNA and b-actin were purchased as Assays-on-de-
mand Products for Gene Expression (Applied
Biosystems). Real-time quantitative reverse transcrip-
tase-PCR was performed with the ABI Prism 7700 Se-
quence Detector (Applied Biosystems). 18S rRNA and
b-actin were selected as internal controls for RNA input
and reverse transcription efficiency with the TaqMan
Human Endogenous Control Plate (Applied Biosys-
tems). All PCR reactions were done in duplicate for
both target genes and internal controls. Relative gene
expressions were presented with the 2)DDCt method [39].
Immunohistochemistry
A representative formalin fixed paraffin embedded tissue
block was selected, five-micrometer sections were cut,
deparaffinised and rehydrated through graded alcohols.
Antigen retrieval was performed by heating the slides in
citrate buffer for 30 min using a warm water bath at
98 C. Endogenous peroxidase was quenched for 10 min
with peroxidase blocking reagent (DakoCytomation,
Glöstrup, Denmark). Primary antibodies , anti-caveo-
lin-1 (1:100; clone 2297; BD Biosciences Pharmingen,
San Diego, CA) and anti-caveolin-2 (1:100; clone 65;
BD Biosciences Pharmingen, San Diego, CA) were
incubated for 60 min at room temperature. Antibody
staining was visualized using the ChemMate Envision
detection system (DakoCytomation). Sections were
counterstained with hematoxylin and mounted for light
microscopy. Caveolin-1 and -2 status of the tumour cells
was evaluated by light microscopy as either positive (any
tumour cell with immunohistochemical staining) or
negative. IHC interpretation was done by 2 independent
observers (GVdE and PV). Interobserver reproducibility
was excellent (j-value caveolin-1 and -2 : 0.91). For a
few discrepant cases slides were reviewed and a con-
sensus was reached.
From 46 of 62 tumour specimens, 15 IBC and 31
non-IBC, RhoC protein expression was determined
using a tissue microarray (TMA) we previously vali-
dated [31]. Briefly, a TMA containing 34 IBC and 41
non-stage matched non-IBC tumours was constructed.
After antigen retrieval, IHC staining for RhoC (anti-
body kindly provided by Prof. Dr. C.G. Kleer, 1/750,
1 h) was performed using the ChemMate Envision
detection system (DakoCytomation). Interpretation of
RhoC expression was done as described before [29] and
the results were dichotomised: IHC score 0–1 = 0 and
score 2–3 = 1.
Statistics
Statistical analysis was done using SPSS 12.0 software
(SPSS, Chicago, IL). Median caveolin-1 and caveolin-2
mRNA expression in IBC and non-IBC tumour samples
were compared using a Mann–Whitney U non-para-
metric test. Caveolin-1, caveolin-2 and RhoC protein
expression were compared using Chi-Square statistics
(or Fisher’s Exact Test, if necessary). The correlation
between caveolin-1 and -2 expression at the mRNA and
protein level was analysed using a Spearman’s correla-
tion coefficient and Chi-Square statistics, respectively.
The correlation between RhoC and caveolin-1 and -2
protein expression was analysed using v2 statistics.
Results
Cell line experiments
Using a differential methylation technique utilizing
arbitrarily primed PCR [37], we previously identified 15
distinct hyper- and hypomethylated transcripts in the
SUM149 IBC cell line compared with HMECs [40].
Genomic sequencing [41] was used to identify differen-
tially methylated sequences. BLASTN analysis of iso-
lated sequences revealed that two 249 bp and 248 bp
hypomethylated transcripts, matched BAC clone CTB-
11K1 (AC006159), proximal to chromosomal marker
D7S522, corresponding to the caveolin-1 and caveolin-2
promoters, respectively.
Since hypomethylation of CpG islands in gene pro-
moter regions typically lead to increased gene expres-
sion, RT-PCR and Western blot analysis were used to
measure caveolin-1 and -2 levels in the SUM149 and
SUM190 IBC cell lines relative to HMECs, MCF10As
and the SUM102 non-IBC cell lines. Figure 1 shows the
results of a typical RT-PCR and Western blot experi-
ment (Figure 1). Relative caveolin-1 and -2 mRNA
levels were measured three separate times and found to
differ significantly in the cell lines (One-way ANOVA
p<0.001 and p<0.001, respectively). In the SUM149
and SUM190 cell lines, mean relative caveolin-1 mRNA
expression was significantly higher then in HMEC’s
(Bonferroni’s post hoc test p<0.001 and p = 0.001,
respectively), MCF10A (Bonferroni’s post hoc test
p<0.001 and p<0.001, respectively) and SUM102
(Bonferroni’s post hoc test p<0.001 and p<0.001,
respectively) cell lines. For caveolin-2, significantly in-
creased mean relative mRNA expression in IBC cell
lines compared to HMECs and non-IBC cell lines was
also found, although the difference between the
SUM149 and MCF10A did not reach statistical signifi-
cance (Bonferroni’s post hoc test p = 0.125).
Relative caveolin-1 and -2 protein expression were
also measured three separate times. Mean relative pro-
tein expression significantly differed between the cell
lines (One Way ANOVA p = 0.004 and p = 0.002,
respectively). Mean relative caveolin-1 protein expres-
sion was significantly higher in SUM149 and SUM190
IBC cell lines compared to HMECs (Bonferroni’s post
hoc test p = 0.1 and p = 0.03, respectively) and the
MCF10A (Bonferroni’s post hoc test p = 0.03 and
p = 0.01, respectively) cell line. No statistical significant
difference was found between both IBC cell lines and the
SUM102 non-IBC cell line (Bonferroni’s post hoc test
p = 0.33 and 0.12, respectively). For mean relative
caveolin-2 expression, comparable results were found.
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Table 2 shows the mean relative caveolin-1 and -2
mRNA and protein expression levels in all cell lines
investigated (Table 2).
Human sample experiments
Relative gene expression, measured by cDNA micro-
array analysis, for both caveolin-1 and -2 mRNA was
found to be significantly higher in the human IBC
samples: 1.7 fold for caveolin-1 (p = 0.05) and 1.8 fold
for caveolin-2 (p = 0.04). This was confirmed by real-
time quantitative RT-PCR analysis on the same sam-
ples: median caveolin-1 expression was 1.7 fold higher
(p = 0.02) and median caveolin-2 expression was 2.2
fold higher (p = 0.03) in IBC compared to non-IBC
(Figure 2). Furthermore, a correlation between relative
gene expression for caveolin-1 and -2 in the same sample
was found (q = 0.55, p<0.001).
Table 3 shows the IHC results for caveolin-1 and
caveolin-2 protein expression in IBC and non-IBC.
When the expression of both molecules was considered
separately, no difference was found between IBC and
non-IBC for caveolin-1 (p = 0.24) expression. For
caveolin-2 a statistical trend to overexpression in IBC
(p = 0.09) was found. But 12 out of 29 (41.4%) IBC
specimens did express either caveolin-1 or -2 compared
to only 5 out of 32 (15.6%) non-IBC specimens
(p = 0.03) (Table 3). Again, caveolin-1 and -2 expres-
sion were correlated (p = 0.008). Figure 3 represents
the same zone of an IBC specimen showing IHC stain-
ing for caveolin-1 and caveolin-2 (Figure 3).
RhoC protein expression was significantly different
between IBC and non-IBC: 66.7 % of IBC and 35.5% of
non-IBC tumour specimens expressed RhoC (p = 0.04).
When IBC and non-IBC samples were taken together, a
trend to a correlation between caveolin-1 (p = 0.1) or
caveolin-2 (p = 0.09) and RhoC protein expression was
found. A significant correlation was found between
RhoC expression and the combined caveolin-1 or
caveolin-2 protein expression (p = 0.04) (Table 4).
Discussion
We used a differential methylation technique utilizing
arbitrarily primed PCR [37] to demonstrate hypome-
thylation of the caveolin-1 and -2 promoter in the
SUM149 IBC cell line. The sequences corresponding to
the caveolin-1 and -2 promoters are 4 of the 10 distinct
hypomethylated transcripts that we previously identified
[40] in the SUM149 IBC cell line compared with
HMECs. Engelman et al. demonstrated that hyperme-
thylation of CpG islands in the caveolin-1 promoter was
responsible for decreased caveolin-1 expression in the
Figure 1. RT-PCR and Western blot of caveolin-1 and -2 expression in HMECs and IBC and non-IBC cell lines. (a) Gel electrophoretic image of
RT-PCR amplified caveolin-1 and -2 mRNA in HMECs, MCF10A and SUM102 non-IBC and SUM149 and SUM190 IBC cell lines. GAPDH
was used as a loading control. Increased expression of caveolin-1 and-2 mRNA in SUM149 and SUM190 compared to HMECs, MCF10A and
SUM102 was observed. (b) Western blot image of caveolin-1 and -2 in the same cell lines. b-actin was used as a loading control. Protein levels of
caveolin-1 and-2 mirrored mRNA expression. (HMEC: human mammary epithelial cell; IBC: inflammatory breast cancer).
Table 2. Mean relative caveolin-1 and -2 mRNA and protein expression levels (±SD) in HMECs, MCF10, SUM102, SUM149 and SUM190 cell
lines
HMECs Non-IBC IBC
MCF10A SUM102 SUM149 SUM190
RT-PCR Caveolin-1 45.47 (±13.16) 67.17 (±7.35) 36.63 (±5.07) 144.70 (±19.45) 204.60 (±15.98)
Caveolin-2 32.93 (±8.69) 60.73 (±16.35) 17.57 (±5.30) 95.20 (±15.32) 134.40 (±18.98)
Western Blot Caveolin-1 67.80 (±19.52) 53.43 (±18.24) 83.63 (±32.23) 141.53 (±31.93) 155.97 (±36.75)
Caveolin-2 66.93 (±18.01) 49.00 (±7.50) 102.77 (±17.81) 122.33 (±14.63) 115.24 (±24.66)
Relative caveolin-1 and-2 mRNA and protein levels are higher in IBC compared to non-IBC cell lines. (HMEC: human mammary epithelial cell;
IBC: inflammatory breast cancer)
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MCF-7 and T47-D non-IBC breast cancer cell lines [42].
Since hypomethylation of CpG islands in gene promoter
regions typically lead to increased gene expression
[43,44], caveolin-1 and -2 gene expressions were mea-
sured in IBC cell lines and human tissue samples of IBC
patients using cDNA microarray, RT-PCR and Western
blot analysis. In IBC cell lines a higher mRNA and
protein expression of both caveolin-1 and -2 was dem-
onstrated compared with HMECs, MCF10A and
SUM102 cell lines. The differences in expression be-
tween the two IBC cell lines and the HMECs, MCF10A
and SUM102 cell lines did not always reach statistical
significance, but were obvious and consistent as shown
in Table 2. These results strongly suggest that hypome-
thylation of the caveolin-1 and -2 promoter leads to
increased expression of caveolin-1 and -2 in IBC cell
lines. Increased expression of caveolin-1 and -2 in IBC
cell lines was then confirmed in human samples of IBC
by cDNA microarray and real-time qRT-PCR experi-
ments for mRNA expression and IHC for protein
expression.
IBC is the most aggressive clinical subtype of breast
cancer. The correlation of caveolin-1 expression with
tumour progression varies with the tumour histiotype.
In breast cancer, caveolin-1 is thought to act as a sup-
pressor of tumour growth and metastasis. In breast
cancer cell lines, caveolin-1 levels were inversely corre-
lated to breast cancer progression in vitro and the
overexpression of caveolin-1 resulted in substantial
growth inhibition of breast tumour cells, which nor-
mally had no endogenous caveolin expression [45,46].
Using different animal model systems, Sloan et al. and
Williams et al. demonstrated that caveolin-1 is a sup-
pressor of mammary tumour growth and metastasis in
vivo [47,48]. In human breast cancer tissues caveolin-1
and –2 expression, both at the mRNA and protein level,
were significantly downregulated compared to corre-
sponding normal tissues [49]. Caveolin-1 suppression
correlated closely with that of caveolin-2 in breast can-
cer and caveolin-1 level was inversely correlated with
tumour size. Overexpression of caveolin-1 and -2 in
IBC, therefore seems contradictory. Nevertheless, evi-
dence is increasing that IBC has to be considered as a
biologically separate breast cancer entity. As previously
described, the small GTP binding protein RhoC is
overexpressed in IBC [32]. RhoC plays a key role in the
increased motility, invasion and angiogenesis of the IBC
phenotype [27,28]. Decreased expression of another
gene, Wnt Induced Secreted Protein-3 (or Lost in
Inflammatory Breast Cancer), was also found to be
contributing to the IBC phenotype [50]. In trying to
elucidate signal transduction pathways involved in IBC,
we recently conducted comparative gene expression
profile analysis of human IBC and non-IBC specimens
[30]. When stringent clinical criteria for the diagnosis of
IBC (AJCC) were taken into account, unsupervised
hierarchical cluster analysis separated IBC and non-IBC
specimens, again suggesting that IBC is a separate breast
cancer entity with a distinct molecular signature. The
present results suggest that increased expression of
caveolin-1 and -2 has to be considered as part of this
particular IBC molecular signature. This IBC signature
contains a strikingly high number of NF-jB target genes
Figure 2. Relative gene expression of caveolin-1 and caveolin-2
mRNA measured by quantitative real-time RT-PCR in IBC and non-
IBC human tissue samples. A 1.7 fold increase in caveolin-1 expression
(p = 0.02) and a 2.2 fold increase in caveolin-2 expression (p = 0.03)
was seen in IBC (IBC: inflammatory breast cancer).
Table 3. Immunohistochemical staining results for caveolin-1 and caveolin-2 protein expression in human tissue samples of IBC and non-IBC
IHC caveolin-1 IHC caveolin-2 IHC caveolin-1 or-2
neg pos neg pos neg pos
Non-IBC 30 2 27 5 27 5
IBC 24 5 19 10 17 12
p=0.24 p=0.09 p=0.03
Twelve out of 29 (41.4 %) IBC samples were either caveolin-1 or caveolin-2 positive, compared to 5/32 (15.6 %) non-IBC samples (p = 0.03).
(IHC: immunohistochemistry; IBC: inflammatory breast cancer).
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that are overexpressed compared to non-IBC. In breast
cancer [51], but also in multiple myeloma [52], NF-jB
activation is responsible for invasiveness due to in-
creased cell migration and motility. In the breast cancer
model, this was due to induction of an epithelial-mes-
enchymal transition by TGFbeta that depended criti-
cally on NF-jB signalling, while in multiple myeloma,
the NF-jB target gene caveolin-1 triggered tumour cell
migration. Overexpression of caveolin-1 might contrib-
ute to the unique IBC phenotype, possibly by interac-
tion or regulation of RhoC GTPase activity. As before,
we demonstrated an increased protein expression of
RhoC in IBC compared to non-IBC [31]. Furthermore,
a correlation between caveolin-1 or caveolin-2 and
RhoC protein expression was found. In other cell types,
caveolin-1 has been shown to directly interact and reg-
ulate molecules such as RhoA, a homologue of RhoC
(95% identical) [5,6]. Furthermore, we demonstrated
that pancreatic cancer cells motility is controlled
through interaction of RhoC and caveolin-1 [53]. In the
previous cDNA microarray experiments IBC specimens
were classified as belonging to the basal like subtype
according to Perou et al. [54]. Since caveolin-2 belongs
to the gene set that defines the basal-like subtype,
overexpression of caveolin-2 confirms this classification
of IBC to this subtype, indicative of a worse prognosis.
Although in breast cancer mainly considered to be a
tumour growth and metastasis suppressor, in prostate
[55–60] , bladder [61] and esophageal [62] cancer,
caveolin-1 may function as a tumour promoter. Fur-
thermore, Yang et al. demonstrated an increased
expression of caveolin-1 in prostate cancer and primary
Figure 3. Immunohistochemical staining of caveolin-1 (a) and caveolin-2 (b) in the same tumour region of an IBC resection specimen. Insets
show membranous staining of IBC tumour cells for caveolin-1 and -2 (IBC: inflammatory breast cancer).
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and metastastic breast cancer specimens [63]. Caveolin-1
has also been shown to be essential for VEGF-triggered
multiple myeloma migration. Caveolin-1 depletion by
antisense methodology and administration of
Bortezomib, a proteasome inhibitor, abrogates VEGF-
triggered multiple myeloma migration [52]. The infil-
trative growth pattern of IBC with tumour cell nests
infiltrating between pre-existing tissue components in-
stead of forming a well circumscribed tumour nodule
and the multiple tumour cell emboli suggest an impor-
tant role in the IBC phenotype for molecules involved in
cell motility and migration. In order to reconcile con-
tradictory data on the role of caveolin-1 in tumour
progression, Carver et al. propose a biphasic model of
caveolin-1 in tumour-cell growth and progression in vivo
[4]. At the beginning of oncogenic transformation de-
creased caveolin-1 expression could lead to a growth
advantage but in the later stages caveolin-1 re-induction
could confer a survival benefit by suppressing apoptosis
and allowing acquisition of multidrug resistance. Wil-
liams et al. suggest that caveolin-1 phosphorylation and
mutations may override or inactivate the growth inhib-
itory activity of the caveolin-scaffolding domain [64].
Increased angiogenesis and lymphangiogenesis are
probably necessary for the metastatic potential of IBC.
In IBC increased expression of most angiogenic and
lymphangiogenic mediators and increased blood vessel
and lymph vessel endothelial cell proliferation were
demonstrated [2,3]. Caveolae and caveolin-1 could
coordinate and regulate angiogenic signalling pathways
and modulate vascular tubulus formation. Targetted
downregulation of caveolin-1 expression prevents vessel
maturation in vivo and capillary-tube-like formation in
cell culture, whereas overexpression of caveolin-1 seems
to promote tubule formation in vitro [65,66].
In conclusion, we demonstrated hypomethylation of
the caveolin-1 and -2 promoters leading to increased
expression of caveolin-1 and -2 both at the mRNA and
protein level in IBC, both in cell lines and in human
breast cancer samples. In these samples, a correlation
was found between caveolin-1 or -2 and RhoC protein
expression. These results suggest a role for caveolin-1
and -2 in the aggressive IBC phenotype. Furthermore,
the data confirm our cDNA microarray results classi-
fying IBC as a separate breast cancer entity [30]. Our
results encourage further exploration of the role of
caveolin-1 and caveolin-2 in IBC and its interaction with
RhoC GTPase. Caveolin-1 and-2 might be considered as
new therapeutic targets in IBC. Recently Bortezomib
(Velcade), the first proteasome inhibitor to have shown
anti-cancer activity and reached clinical trials [67], has
also been shown to decrease caveolin-1 expression,
thereby probably targeting both the tumour stroma and
the cancer cells [52].
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